Although disruption of the microtubule (MT) array inhibits myogenesis in myocytes, the relationship between the assembly of microtubules (MT) and the organization of the contractile filaments is not clearly defined. We now report that the assembly of mature myofibrils in hypertrophic cardiac myocytes is disrupted by myoseverin, a compound previously shown to perturb the MT array in skeletal muscle cells. Myoseverin treated cardiac myocytes showed disruptions of the striated Z-bands containing a-actinin and desmin and the localization of tropomyosin, titin and myosin on mature sarcomeric filaments. In contrast, MT depolymerization by nocodazole did not perturb sarcomeric filaments. Similarly, expression of constitutively active stathmin as a non-chemical molecular method of MT depolymerization did not prevent sarcomere assembly. The extent of MT destabilization by myoseverin and nocodazole were comparable. Thus, the effect of myoseverin on sarcomere assembly was independent of its capacity for MT inhibition. Furthermore, we found that upon removal of myoseverin, sarcomeres reformed in the absence of an intact MT network. Sarcomere formation in cardiac myocytes therefore, does not appear to require an intact MT network and thus we conclude that a functional MT array appears to be dispensable for myofibrillogenesis. Cell Motil. Cytoskeleton 65: 40-58, 2008. '
INTRODUCTION
Microtubules (MT), highly dynamic polymers of heterodimeric a/b tubulin subunits, are involved in important and complex biological processes such as cell division, wound healing and cell movement. The roles of the MT network however are not restricted to cycling cells. In muscle cells, the MT network may also be involved in regulating differentiation as well as disease progression [Toyama et al., 1982; Ehler and Perriard, 2000; Perez et al., 2002] .
During myogenesis in skeletal muscle, individual mono-nucleated myoblasts fuse to form elongated multinucleated myotubes. This is accompanied by the complete reorganization of the MT network from centrosome-nucleated polar filaments that radiate towards the plasma membrane to a non-centrosomal, parallel network that runs longitudinally along the long axis of the myotube [Warren, 1974; Tassin et al., 1985; Saitoh et al., 1988] . MT reorganization occurs concomitantly with myofibrillogenesis as contractile filament proteins are expressed and assembled into sarcomeres [Sanger et al., 2002] .
There are several models of myofibrillogenesis but the most compelling involve the initial formation of premyofibrils. These immature pre-myofibrils consist of mini-sarcomeres on actin thin filaments bounded by aactinin containing Z-bodies . As premyofibrils mature, muscle myosin proteins replace nonmuscle isoforms to form the thick-filament A bands, titin is incorporated to stabilize the sarcomeres and Z-bodies aligned laterally are merged into Z-lines . Despite this understanding of the function of contractile filament proteins in myofibrillogenesis, comparatively little is known about the requirement, if any, of the MT cytoskeletal array in regulating this process.
The observation that MTs are closely aligned with myofibrils has prompted suggestions that MTs may be involved in myofibrillogenesis [Saitoh et al., 1988] . It is unclear whether MTs are physically linked to contractile filaments although there may be an association through the muscle RING finger family of proteins [Spencer et al., 2000; McElhinny et al., 2004] . A function in skeletal muscle differentiation was supported by findings that disrupting the MT network, specifically the stabilized ''long-lived'' MT sub-population as defined by the Cterminal detyrosination of a-tubulin (also known as 'Glu' MTs), blocked the fusion of skeletal myoblasts into myotubes [Toyama et al., 1982; Gundersen et al., 1989; Chang et al., 2002] . Furthermore, treatment of differentiated amphibian and mammalian skeletal myotubes in culture with MT binding agents induced ''cellularization'', the reversal of differentiated multi-nucleated myotubes to single mono-nucleated cells [Rosania et al., 2000; Perez et al., 2002; Duckmanton et al., 2005] . Although sarcomeres are disassembled during this dedifferentiation process, it is unclear whether the breakdown of sarcomeres is a direct consequence of MT loss or occurs subsequent to cellularization.
Previously, some groups had suggested that MTs could replace thin filaments as scaffolds for the formation of myofibrils [Antin et al., 1981; Toyama et al., 1982] . More recently, it has also been proposed that sarcomeric myosin is transported along MTs and directed to the site of assembly during myofibrillogenesis in skeletal muscle [Pizon et al., 2005] . In contrast, a recent study has indicated that MTs could not serve as scaffolds for sarcomere formation [Siebrands et al., 2004] . The requirement for MTs in sarcomere assembly was also contradicted by findings that myofibrils did not form in the absence of actin thin filaments in latrunculin-A treated myocytes despite the presence of the microtubule network . This indicated that the MT network in itself is not sufficient for myofibrillogenesis. Furthermore, MT depolymerization with nocodazole in embryonic cardiac myocytes did not prevent the assembly of new sarcomeres [Ehler and Perriard, 2000] . Therefore, it is clear that the precise role of the MT array in the assembly of sarcomeres and myofibrillogenesis has not been completely elucidated.
In the current study, we have evaluated the requirement of MTs in a neonatal cardiac myocyte model of myofibrillogenesis during hypertrophy using the MT depolymerizing agents myoseverin and nocodazole. Nocodazole is traditionally used as an anti-neoplastic agent owing to its anti-MT effects [De Brabander et al., 1976] . Myoseverin was more recently identified in a library screen of tri-substituted purines and its MT depolymerizing activity was initially characterized in cultured skeletal myotubes [Rosania et al., 2000] . We report that both myoseverin and nocodazole induced MT disassembly, but only myoseverin perturbed the contractile sarcomeric array in myocytes. Furthermore, sarcomeres reformed in the absence of an intact MT array when myoseverin was removed from cells. In addition, overexpression of a negative regulator of MT assembly, stathmin, did not perturb sarcomeres. Thus, we conclude that a functional MT array is dispensable for sarcomere assembly and myofibrillogenesis.
MATERIALS AND METHODS

Antibodies and Reagents
Anti-a-tubulin was from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). FITC conjugated phalloidin was from Molecular Probes (Eugene, OR, USA) and Cy2/Cy3 conjugated secondary antibodies were from Chemicon (Temecula, CA, USA). Sarcomeric aactinin, tropomyosin and titin antibodies, myoseverin, nocodazole and taxol were purchased from SIGMAAldrich (Saint Louis, MO, USA). Cardiac myosin heavy chain antibody was from Abcam (Cambridge, UK). All cell culture reagents were from GIBCO (Carlsbad, CA, USA) and all general reagents used were of analytical grade and supplied by SIGMA-Aldrich.
Primary Cardiac Myocyte Isolation and Treatment
Neonatal cardiac myocytes were isolated from the hearts of 1-to 2-day-old Sprague-Dawley rats as previously described [Ng et al., 2001] . Briefly, ventricular cells were isolated by collagenase treatment and then preplated to deplete the culture of non-myocytes. Cells were then plated on to laminin-coated glass coverslips for microscopy. Cells were then washed into serum-free maintenance medium for up to 12-16 h prior to commencing experimental protocols. For adenoviral mediated overexpression of constitutively active stathmin (Op18-tetraA), cardiac myocytes were exposed to viral particles at 5 multiplicity of infection (moi) for 2 h before replacing with serum-free medium. Hypertrophy was induced by treatment with phenylephrine (PE, 100 lM) or leukemic inhibitory factor (LIF, 10 ng/ml) for 24 h after serum was removed from the culture medium. MT depolymerization with myoseverin (20 lM) and nocodazole (20 lM or 0.5 lM) was for either 6 or 16 h as indicated. In wash-out experiments, MT inhibitors were removed by four changes in serum-free media before finally incubating in serum-free media supplemented with PE for the indicated times.
Skeletal Myotube Culture and Treatment C2C12 myoblasts, purchased from the American Type Culture Collection (Manassas, VA, USA), were of an early passage number (<6 passages) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), L-glutamine and penicillin/streptomycin. Mono-nucleated myoblasts were induced to differentiate into myotubes by culturing in low-serum differentiation medium (DMEM supplemented with 1% FBS, L-glutamine and penicillin/streptomycin) for between 5 and 7 days. The myotubes were then treated with MT inhibitors for 6 h before fixing for microscopic analysis.
Adenoviral Constructs
Adenoviral constructs expressing constitutively active stathmin tetraA (pAd-Op18tetraA) were generated using the AdEasy system following manufacturer's instructions (Stratagene). Briefly, Op18-tetraA was subcloned into pAdtrack-CMV shuttle vector which also expresses GFP. This was then recombined with pAdEasy-1 in electro-competent BJ5183 cells. Cells containing recombinated pAd-Op18tetraA was then selected for with kanamycin and the plasmid expanded and extracted. Generation of virus was by lipofectaminemediated transfection into Ad293 cells. Viral particle production was tracked by GFP expression, expanded, isolated and purified for infection of neonatal cardiac myocytes.
Immunofluorescence Microscopy
Immunofluorescent staining and microscopic analyses of cells were performed as previously described [Ng et al., 2006] . Briefly, following experimental treatments, cells grown on glass coverslips were fixed in 4% (w/v) paraformaldehyde, permeabilized with 0.2% (v/v) Triton X-100 in PBS, and blocked with 10% (v/v) fetal calf serum in PBS. Cells were then stained with primary antibodies diluted (1:100) in 1% (w/v) BSA in PBS and detected with Cy2/Cy3 conjugated secondary antibodies (1:400 in 0.1% [w/v] BSA in PBS). The cells were then mounted and examined by confocal microscopy using a BIO-RAD MRC 1000/1024 UV laser scanning confocal microscope.
Tubulin Polymer Fractionation and Immuno-blotting
The assay to measure polymerized tubulin versus soluble tubulin specifically was performed as described previously [Ng et al., 2006] . In brief, cardiac myocytes were lysed in a MT-stabilizing buffer (0.1 M Pipes, pH 6.9, 2 M glycerol, 5 mM MgCl 2 , 2 mM EGTA, 0.5% Triton X-100 and protease inhibitors) supplemented with 4 lM taxol to maintain MT stability during isolation. Polymerized tubulin was then pelleted by centrifugation (20,000g for 45 min) leaving solubilized tubulin in the clarified supernatant. The pellet was then separated from the supernatant, washed twice in lysis buffer and denatured in laemmli buffer. Pellet and supernatant fractions were then resolved on SDS-PAGE and immuno-blotted for a-tubulin.
RESULTS
Myofibrillogenesis and MT network proliferation in neonatal cardiac myocytes
In the current study, primary isolated neonatal rat cardiac myocytes were used as a cell model to evaluate the molecular events in myofibrillogenesis. Previously, studies in cultured cell and animal models had suggested that MT proliferation correlated with increased protein synthesis and myofibrillogenesis during the induction of hypertrophy [Watkins et al., 1987; Ishibashi et al., 2003] . Firstly, we sought to confirm that similar cytoske-letal reorganization occurred in the neonatal cardiac myocytes. These cells exhibit increased sarcomere assembly and reorganization in response to hypertrophic agonist treatment such as the a-adrenergic coupled receptor agonist, PE, or the IL-6 family cytokine, LIF [Aoki et al., 1998; Ng et al., 2001 ]. In Fig. 1a , control neonatal cardiac myocytes, stained with phalloidin to observe actin within the contractile thin filaments, were irregularly shaped with thin filaments that appeared punctuate and non-striated. This was distinctive of myocytes whereas non-myocytes typically exhibit a faint, non-punctate, linear stress fiber pattern when stained with phalloidin (data not shown). Next, cells exposed to PE or LIF for 24 h became elongated in cell shape and actin staining showed a striated pattern of thin filaments (Figs. 1b and 1c) . Co-staining with a-tubulin for the MT array also demonstrated an increase in MT filaments in the hypertrophic cardiac myocytes (Fig. 1 , compare control panel d with hypertrophic cells in panels e and f). In addition, MTs in cardiac myocytes radiated from the peri-nuclear membrane (Figs. 1d-1f ). This further distinguished myocytes from non-myocytes in our culture where the MTs are anchored predominantly to the centriole (data not shown). These results confirm that MT hyperproliferation, as observed during pressure overload hypertrophy of adult heart tissue [Zile et al., 2001 ] is also observed in primary cultures of neonatal cardiac myocytes.
Closer observation of the striated hypertrophic cardiac myocytes was possible following the staining for actin ) and a-actinin that revealed the Zbands bordering each sarcomere . The actin thin filaments in control treated cardiac myocytes ( Fig.  1g ) stained for a-actinin in punctuate Z-bodies that were not laterally aligned (Fig. 1j ). This is consistent with previous reports that a-actinin was localized to Z-bodies on pre-myofibrils . In response to PE and LIF, a-actinin staining showed striations aligned in parallel and localized to the Z-lines indicative of mature myofibrils (Figs. 1h, 1i, 1k, and 1l) . These results show myofibrillogenesis with concomitant MT proliferation during the hypertrophy of neonatal cardiac myocytes and suggest that this is a valuable cell system to study the relationship between sarcomeric organization and MT assembly.
Myoseverin Treatment Induced Sarcomere Disassembly in Hypertrophic Cardiac Myocytes
To study the relationship between sarcomeric organization and MT assembly, we next tested the effects of the MT depolymerizing drugs, nocodazole and myoseverin, on altered sarcomeric assembly in hypertrophic cardiac myocytes. Whereas control DMSO-pretreated cardiac myocytes showed a cross-striated actin filament staining pattern in response to PE (Fig. 2a) , myoseverin (20 lM), when added prior to PE stimulation, inhibited the formation of sarcomeres (Fig. 2b) . In contrast, nocodazole (20 lM) did not prevent the assembly of sarcomeres although the parallel alignment of fibrils was altered with several fibrils running at oblique angles to one another (Fig. 2c) . In contrast to the effects noted for myoseverin, nocodazole induced an increase in sarcomeric assembly even in the absence of hypertrophic agonist stimulation (Suppl. Fig. 1 ). Staining for a-tubulin confirmed that the MT array was perturbed by both drugs . Specifically, myocytes treated with myoseverin retained short MT fragments that were evenly dispersed throughout the cell (Fig. 2e) whereas nocodazole, at the same concentration, induced a complete loss of the MT array (Fig. 2f) . Thus, myoseverin, but not nocodazole, treatment arrested sarcomeric assembly in hypertrophic cardiac myocytes.
We then investigated how myoseverin might alter preformed myofibrils by adding the agent to cells that had already hypertrophied in response to PE (100 lM, 24 h). We found that following myoseverin (20 lM, 16 h) addition to hypertrophic cells, the pre-assembled striated sarcomeres of mature myofibrils were no longer observed and were instead replaced by a non-striated punctate staining pattern ( Fig. 2g versus Fig. 2h ). In contrast, nocodazole (20 lM, 16 h) treatment did not induce the disassembly of striated sarcomeric filaments in PEstimulated myocytes (Fig. 2i) despite completely depolymerizing the MT array (compare Fig. 2j with Fig. 2l ). Furthermore, myocytes treated with nocodazole exhibited a stellate morphology with pointed or barbed ends. This is reminiscent of stress fiber formation seen in nonmyocyte cells during MT depolymerization and mostly likely a result of focal adhesion complex formation [Ezratty et al., 2005] . The striations in Fig. 2i were also present in higher density and appeared more compact. This was typically seen, although not in all cases, in cells co-treated with nocodazole and a hypertrophic agonist and reflects an enhanced progression of sarcomeric reorganization not dissimilar to striations observed with prolonged treatment (>48 h) with a hypertrophic agonist alone (data not shown). These results indicate that, in contrast to myoseverin, co-treatment with nocodazole did not disassemble sarcomeres and may enhance myofibrillogenesis in cardiac myocytes.
Upon further investigation, myoseverin treatment in hypertrophic myocytes completely disassembled sarcomeres within as little as 6 h following drug treatment (data not shown). The phalloidin stained filaments in myoseverin treated hypertrophic myocytes resembled the pre-myofibril filaments in untreated non-hypertrophic cells with the exception that the filaments were more abundant (compare Fig. 2h with Fig. 1g) . A similar effect on sarcomeres in LIF-stimulated cardiac hypertrophy was observed in response to myoseverin treatment (data not shown). Thus, myoseverin induced myofibril disassembly of organized sarcomeres in hypertrophic cardiac myocytes.
To determine whether the differential effects on the sarcomeric cytoskeleton were due to the varying degrees of MT loss, we next compared the effect of myoseverin to the effects following exposure to a lower concentration of nocodazole. The MT network was not completely lost in response to myoseverin treatment when compared to the same concentration of nocodazole (e.g., Figs. 2e and 2f). A lower dose of nocodazole (0.5 lM, 6 h) perturbed the MT array to the same extent as the higher dose of myoseverin (20 lM, 6 h) (compare Fig. 3 , panel b versus panel d). This is consistent with a previous report that nocodazole was more potent than myoseverin in inducing cellularization of mammalian myotubes [Duckmanton et al., 2005] . Co-staining with phalloidin confirmed that striated sarcomere morphology was not affected by either a low or high dose of nocodazole (Figs. 3c and 3e), despite its disruption of MTs (Figs. 3d and 3f), confirming that nocodazole did not perturb sarcomere assembly.
We further investigated whether there were differential effects on the stable MT sub-population by staining for detyrosinated, or Glu-tubulin, as this MT subset is specifically involved in early myogenesis [Chang (Fig. 4f) . As noted previously, treatment with myoseverin, but not nocodazole, disrupted sarcomeric organization (Figs. 4a, 4c, and 4e) . Therefore, the effect of myoseverin on the MT array was indistinguishable from a functionally equivalent lower dose of nocodazole. Taken together, these results indicated that despite similar effects on MT depolymerization, the inhibition of myofibril organization was specific to myoseverin.
MT Depolymerization by Constitutively Active Stathmin Overexpression Did Not Disassemble Sarcomeres
Because our comparisons of the effects of myoseverin with nocodazole suggested that the effect of myoseverin on myofibril assembly was independent of its MT depolymerizing capacity, we evaluated this by comparing the effects of myoseverin with a non-pharmacological inhibitor of MT assembly. Specifically, we used a viral expression system to express a constitutively active non-phosphorylatable form of a MT destabilizing protein, stathmin (also known as oncoprotein 18 [Op18]), in cardiac myocytes. Op18 binds a-/b-tubulin heterodimers to induce MT disassembly and this activity is negatively regulated by phosphorylation on multiple serine residues in the C-terminal half of the protein [Horwitz et al., 1997] . In the constitutively active Op18-tetraA mutant, the serine phosphorylation sites have been substituted for alanine. The adenoviral mediated Op18-tetraA expression in non-hypertrophic myocytes was sufficient to induce sarcomeric reorganization in the absence of agonist treatment (Figs. 5a and 5b) . In contrast, myocytes which did not exhibit Op18-tetraA expression retained a typical punctuate premyofibril staining pattern (Fig. 5a, see arrow) . As expected from the results with nocodazole (Fig. 3) , the mutant Op18-tetraA expression did not disrupt striated phalloidin-stained actin thin filament bands in PE-treated myocytes (Figs. 5c and 5d) . As a control, we demonstrated that infection with virus encoding GFP did not promote myofibril assembly in control cells (Figs. 5e and 5f ). We confirmed that the MT network remained intact in cells expressing GFP only (Suppl. Figs. 2a and 2b ) but was disrupted in cells expressing Op18-tetraA (Suppl. Figs. 2c and 2d) . These results suggest that MT network perturbation did not lead to sarcomere disruption but rather promoted sarcomeric assembly in cardiac myocytes.
Characterization of Myoseverin Disrupted Myofibrils With Sarcomeric Protein Antibodies
Although myoseverin treatment disrupted sarcomere assembly in hypertrophic cells as indicated with phalloidin staining (Figs. 2-4) , phalloidin only stains the actin thin filaments and does not directly reveal the localization of sarcomeric proteins. Thus, we subsequently used an antibody specific for sarcomeric a-actinin in our staining protocols. Staining of control cells indicated the presence of a-actinin on Z-bodies which colocalized with the puncta present on phalloidin stained actin filaments (Figs. 6a and 6b) . Following exposure to PE, a-actinin Z-bodies were aligned laterally into the distinctive Z-bands on the boundaries of sarcomeres (Fig. 6c) . This is consistent with the premyofibril model of myofibrillogenesis Sanger et al., 2005] . In response to myoseverin (20 lM, 6 h), the aactinin antibody stained Z-bands in hypertrophic myocytes were disrupted and reverted to punctuate Z-bodies similar to the premyofibrils in non-hypertrophic cells (Fig. 6 , compare panel e with panel a). These a-actinin stained Z-bodies colocalized with phalloidin stained actin filaments which, unlike the curved filaments in control cells, were organized as linear bundles towards adhesion points along the periphery of the cell (Fig. 6f) . These actin filaments in myoseverin treated cells were reminiscent of stress-fibre like structures in non-myocytes. However, positive co-staining with a-actinin confirmed that these were muscle cells (Fig. 6e) .
We next stained for tropomyosin that is localized to sarcomeric structures in cardiac myocytes [Wang et al., 1988] . Sarcomeric tropomyosin colocalized with phalloidin stained actin filaments in control cells indicating that these filaments were premyofibrils (Figs. 7a and  7b ). Tropomyosin staining in hypertrophic cells induced with PE stimulation showed a banding pattern (Fig. 7c) which was co-ordinated with phalloidin stained actin (Fig. 7d) . In response to myoseverin, this banding pattern was disrupted so that the tropomyosin staining revealed few distinctive structures (Fig. 7e) . The lack of tropomyosin staining on contractile actin thin filaments (Fig.  7f) indicates the disruption of sarcomeres in myoseverintreated cardiac myocytes.
Additionally, we examined the localization of the intermediate filament protein, desmin, in hypertrophic cardiac myocytes treated with mysoseverin and nocodazole. Desmin is colocalized to sarcomeric bands in mature myofibrils surrounding the a-actinin containing Z-disk and is required to maintain the stability of sarcomeres [Samuel et al., 1985] . Desmin staining in control myocytes appeared to be localized to filamentous structures, in a wavy pattern that did not co-localize with actin filaments (Figs. 8a and 8b ). Myocytes treated with PE displayed a banding pattern with desmin localizing to the Z-line as expected (Figs. 8c and 8d ). This is in agreement with a previous report that banded desmin staining was only observed in cultured cardiac myocytes that had undergone an advanced stage of myofibril organization (Ehler et al., 1999) . In response to myoseverin, desmin stained Z-bands in hypertrophic myocytes were completely dispersed and no discernible structures could be observed (Figs. 8e and 8f) . This was consistent with the effects of myoseverin on the localization of a-actinin and tropomyosin.
We next examined myoseverin treatment on the localization of titin, the largest described protein in the cell that spans from the M-band to the Z-disk and is required for sarcomere formation [Musa et al., 2006; Weinert et al., 2006] . We utilized an antibody that specifically recognized an epitope (T11) on the A-I junction region of the titin molecule [Furst et al., 1988] . During myofibrillogenesis in myocytes, titin is found on mature myofibrils but not premyofibrils [Wang et al., 1988; Dabiri et al., 1997; Sanger et al., 2005] . We confirmed this to be the case as control cardiac myocytes did not stain for titin (Figs. 9a and 9b) . In response to PE treatment, titin was expressed and localized to striated bands in line with sarcomere formation (Figs. 9c and 9d) . As with tropomyosin and desmin, exposure of PE-treated myocytes to myoseverin resulted in the complete disruption of striated titin bands (Figs. 9e and 9f) .
Lastly, we looked at the distribution of sarcomeric cardiac myosin in myoseverin treated hypertrophic cardiac myocytes. In the premyofibril model of myofibrillogenesis, myosin is localized to sarcomeric filaments in nascent myofibrils, an intermediate stage of sarcomeric assembly before the formation of mature myofibrils . Staining with an antibody to myosin heavy chain revealed that the actin containing thin filaments in non-hypertrophic control cardiac myocytes were devoid of sarcomeric myosin (Figs. 10a and 10b) . In contrast, mature myofibrils in hypertrophic cardiac myocytes contained striated myosin (Figs. 10c and 10d) . Following myoseverin treatment, sarcomeric myosin was no longer found on phalloidin stained actin filaments (Figs. 10e and 10f ). This indicated that the residual phallodin stained filaments in myoseverin treated cells most closely resembled pre-myofibrils as oppose to nascent or mature myofibrils. Taken together, staining of sarcomeric proteins indicated that myoseverin treatment disassembled mature myofibrils in hypertrophic myocytes to a stage reminiscent of early myofibrillogenesis. Neonatal cardiac myocytes were stained with anti-aactinin to visualize Z-bands (a, c, e) and phalloidin-FITC for actin filaments (b, d, f) . Actin thin filaments in control myocytes were decorated with punctate a-actinin staining (a, b). In response, to PE treatment (100 lM, 24 h), cells displayed sarcomeric bands bordered by a-actinin stained Z-lines (c, d). In response to subsequent myoseverin treatment (20 lM, 6 h), the sarcomeric bands were lost (e, f). Bar, 20 lm.
Myoseverin Disrupts Sarcomeres in Skeletal Myotubes
We report for the first time the disruptive effect of myoseverin on the sarcomeric array in cardiac myocytes. Previously, myoseverin had been reported to not perturb the actin cytoskeleton [Rosania et al., 2000; Perez et al., 2002] . However, it is unclear whether an effect on sarcomere assembly in skeletal myocytes was investigated. Therefore we sought to determine whether myoseverin could similarly perturb mature myofibrils in skeletal muscle. Skeletal myotubes in culture, resulting from differentiation and fusion of C2C12 myoblasts, displayed striated myofibrils when stained for Z-band localized aactinin (Fig. 11a) . However, the striations were rapidly disrupted (<6 h) in response to myoseverin treatment (Fig. 11b) . In contrast, myofibrils were unaffected in response to nocodazole treatment at either high (20 lM, Fig. 11c ) or low (0.5 lM, Fig. 11d ) concentrations. Thus, myoseverin also induced a similar breakdown in myofibril assembly in skeletal muscle cells.
Recovery of Sarcomere Organization Following Removal of Myoseverin
Myoseverin inhibition of MTs in skeletal myocytes was previously shown to be reversible [Rosania et al., 2000; Perez et al., 2002] . It was of therefore of interest to determine whether the myoseverin-induced breakdown of sarcomeric organization was similarly reversible in cardiac myocytes. First, we sought to confirm the transient effects of myoseverin on MT disassembly in cardiac myocytes. As previously indicated, the MT array in untreated myocytes radiate from the peri-nuclear membrane to the cell periphery (Fig. 12A, a) . Following exposure to myoseverin (20 lM, 6 h), only short MT fragments interspersed in the cytoplasm remained (Fig.  12A, b) . In contrast to previous reports for skeletal myotubes [Rosania et al., 2000] , the MT array in cardiac cells was not re-established following wash-out of myoseverin from the culture medium for up to 16 h (Fig. 12A , compare panels c and d with panel b). As a control, we demonstrated that despite a greater degree of MT ablation, nocodazole wash-out resulted in the complete return of the MT array within 2 h (Fig. 12A, e-g ). Western blotting for a-tubulin indicated that very little a-tubulin remained in either soluble or pellet fractions from cell lysates following myoseverin treatment (20 lM, 6 h, Fig.  12B ). In nocodazole treated cells, the majority of a-tubulin was present in the soluble fraction reflecting the depolymerized state of a-tubulin in these cells (Fig.  12B) . As a control, taxol treatment shifted the majority of a-tubulin to the pellet fraction indicating the increase in the polymerized state (Fig. 12B) . These results suggest that the severely reduced a-tubulin protein content in myoseverin treated cells may lead to the failure of cardiac myocytes to re-establish the MT array following myoseverin removal. In support of this, the MT array was returned within 24 h following wash-out of myoseverin-treated cardiac myocytes into media containing serum (data not shown). The initial characterization of reversible myoseverin effects on MT assembly were performed on immortalized skeletal myocytes (C2C12) [Rosania et al., 2000] . Therefore, it is possible that myoseverin may exhibit differential effects on primary myocyte cultures of cardiac origin.
In light of the effects on the MT array, we investigated whether assembled sarcomeres were returned following myoseverin removal. As described, myoseverin treatment stimulated the loss of the cross-striated banding pattern in PE-treated cardiac myocytes and perturbed the MT array (Figs. 13a-13d) . Following washout of myoseverin into serum-free medium, we observed that the sarcomeric banding started to return by 2 h (Fig. 13e,  arrowheads) . Co-staining with a-tubulin confirmed that the MT network remained perturbed in this cell (Fig.  13f) . Within 16 h after myoseverin wash-out, a distinctive striated sarcomeric staining pattern had returned despite the disrupted MT array (Figs. 13g and 13h) . Thus, myoseverin induced myofibril disassembly is reversible in cardiac myocytes. As sarcomeres are reassembled in the absence of an intact tubulin polymer array, MT function, at least in myocytes of cardiac origin, does not appear to be required for myofibrillogenesis.
DISCUSSION
Myoseverin Is a Dual-Action Disruptor of the Cytoskeleton
We report that the myofibril network can be disrupted by myoseverin. Specifically, we have shown that myoseverin pre-treatment prevented sarcomeric organization and arrested myofibrillogenesis during the hypertrophy of cardiac myocytes. Furthermore, myoseverin exposure resulted in the disassembly of mature myofibrils in hypertrophic cardiac myocytes. The cross-striated banding pattern of a number of sarcomeric proteins (a-actinin, tropomyosin, desmin, titin and myosin) was rapidly rendered diffuse or was disrupted following myoseverin treatment. Mature myofibrils were broken down to filaments containing a-actinin Z-bodies but lacking the mature sarcomeric proteins titin, tropomyosin and desmin. This process was reversed upon myoseverin removal. Thus, our observations support the pre-myofibril model of myofibrillogenesis .
Previously, the inhibition of myofibrillogenesis had been shown following various experimental treatments. For example, methane sulfonate compounds arrested myofibrillogenesis at the premyofibril state in embryonic cardiac myocytes [Golson et al., 2004] . However, these compounds did not affect mature myofibrils. Similarly, latrunculin-A, an inhibitor of actin polymerization, prevented the formation of premyofibrils but did not perturb mature myofibrils . Mature myofibrils are however disassembled by the overexpression of an N-terminal fragment of titin or by phorbol ester treatment [Lin et al., 1987; Turnacioglu et al., 1997] . However, these treatments have not been shown to perturb the MT array whereas myoseverin displays an apparent dual action in inhibiting both myofibrils and polymerized tubulin. Thus, myoseverin represents a potentially valuable tool in investigating the relationship between the sarcomeric and microtubular array in the complex process of cardiac myogenesis.
MTs Are Not Required for Sarcomeric Organization
Studies have suggested a role for the MT network in regulating cardiac disease. Excessive MT proliferation has been reported in animal models of pressure overload cardiac hypertrophy and in end-stage failing human Fig. 10 . Sarcomeric myosin is disrupted by myoseverin. Cardiac myocytes were stained for cardiac myosin heavy chain (a, c, e) and phalloidin-FITC (b, d, f) . In nonhypertrophic cardiac myocytes (Control), sarcomeric myosin staining was not observed (a). Costaining for phallodin actin confirmed the absence of sarcomeres (b). In hypertrophic cells (PE, 100 lM, 24 h), myosin staining was striated and localized to sarcomeres (c, d) . In response to myoseverin (20 lM, 6 h) the cellular distribution of myosin became diffuse and did not co-localized to phalloidin stained structures (e, f). Bar, 20 lm.
hearts [Cooper IV, 2000; Ehler and Perriard, 2000; Zile et al., 2001] . MT hyperproliferation observed during hypertrophy occurs simultaneously with elevated protein synthesis, increased myofibrillogenesis and remodeling of the sarcomeric cytoskeleton [Ehler and Perriard, 2000; Hein et al., 2000] . Although cardiac hypertrophy involves significant reorganization of both sarcomeric and MT arrays, it is unclear whether the two processes are linked. We report the significant finding that myoseverin disassembled both MTs and sarcomeres and that a 'functionally' equivalent dose of nocodazole destabilized MTs to the same extent as myoseverin but displayed the opposite effect on sarcomeric organization. This is in agreement with the observation that myofibrillogenesis was not impeded in nocodazole treated cultured embryonic cardiac myocytes [Ehler and Perriard, 2000] . To clarify this situation, we destabilized MTs without chemical manipulation. Constitutively active Op18 expression perturbed the MT array but did not affect sarcomere assembly in cardiac myocytes. Therefore, we conclude that an intact MT array is not required for sarcomeric organization in cardiac myocytes.
Our results contradict the previous suggestion that active trafficking of myosin along MTs is essential for sarcomere assembly in skeletal myocytes [Pizon et al., 2005] . The possibility remains that MT functions differ between skeletal and cardiac myocytes as there are subtle differences in sarcomere assembly between muscle types [Lloyd et al., 2004] . Furthermore, Pizon and colleagues make the distinction that nocodazole induced MT disassembly only affected new sarcomere assembly as nascent myofibrils but not mature myofibrils were lost [Pizon et al., 2005] . In our cardiac myocyte model, no mature myofibrils were observed in non-hypertrophic control cells as titin staining (Fig. 9 ) and Z-line desmin staining was not present (Fig. 8) . Therefore, mature sarcomeres are formed de novo in response to hypertrophic agonist stimulation in these cells. We found that MT depolymerization with nocodazole or Op18-tetraA expression did not prevent the formation of mature myofibrils in cardiac myocytes in response to PE treatment. In addition, we observed that myocytes treated with nocodazole or expressing Op18-tetraA tended to develop organized sarcomeres without the need for PE treatment although the effect of the latter was additive. Thus, we conclude that new sarcomere assembly is likewise not perturbed when MTs are lacking. Lastly, sarcomere disassembly was rapidly reversed following washout of myoseverin in the absence of an intact MT array. From this we conclude that, although MT perturbation affects myogenesis, there does not seem to be an intrinsic function for the MT array in sarcomerogenesis.
Myoseverin as a MT Destabilizing Agent
The initial characterization of myoseverin described its actions to disassemble MTs in a manner superficially similar to classical inhibitors of MTs (eg. nocodazole) but without the associated cellular toxicity [Rosania et al., 2000; Perez et al., 2002] . However, we have now shown that myoseverin is a far less potent MT inhibitor given that its effects on the total MT array and stable Glu-MT subsets are only comparable to a 40-fold lower concentration of nocodazole (Figs. 3 and 4) . In addition, the extent of MT perturbation by myoseverin did not increase substantially with increased concentration indicating a maximal effect at this dose (20 lM, data not shown). This is consistent with the recent demonstration that there were no differences in skeletal myogenic dedifferentiation or toxicity when myoseverin was compared with a lower dose of nocodazole (0.5 lM) [Duckmanton et al., 2005] .
Little is known on the mechanism by which myoseverin depolymerizes MTs. Myoseverin was shown to bind tubulin with the implication that this binding destabilized the tubulin polymer [Rosania et al., 2000; Perez et al., 2002] . However, we have now shown that myoseverin treatment greatly reduced tubulin expression (Fig. 12) . This effect was not replicated by nocodazole. As monomeric tubulin was not degraded, MTs were rapidly reassembled following removal of nocodazole (Fig.  12) . In contrast, myoseverin-treated cells required the presence of serum, presumably for de novo tubulin synthesis, before regeneration of the MT network. Although the downregulation of tubulin could occur subsequent to Fig. 13 . Sarcomere reassembly following removal of myoseverin. Cardiac myocytes were co-stained with phalloidin (a, c, e, g) and atubulin (b, d, f, h) to visualize sarcomeres and the MT array, respectively. Cardiac myocytes were treated with PE (100 lM, 16 h) to induced sarcomeric assembly (a) and MT densification (b). PEtreated cells were subsequently treated with myoseverin (20 lM, 6 h) to disrupt sarcomeres (c) and the MT array (d). Recovery of the sarcomeres and MTs were then investigated at 2 h (e, f) and 16 h (g, h) after wash-out of cells into serum-free culture media.
MT depolymerization, our observations raises the possibility that myoseverin may destabilize MTs indirectly through reducing the pool of monomeric tubulin. This may be via it promoting tubulin degradation. Further testing is required to confirm this hypothesis. More generally, it appears that myoseverin and classical MT depolymerizing agents inhibit the MT array via different mechanisms.
Implications for Myogenesis
MT inhibitors have previously been shown to induce dedifferentiation of skeletal myotubes in culture with perturbation of the MT array sufficient to induce cellularization of multi-nucleated myotubes [Rosania et al., 2000; Perez et al., 2002; Duckmanton et al., 2005] . However, we have shown that MT disruption in itself does not lead to the disassembly of myofibrils. Rather myofibril disassembly appears to be intrinsic in these cultured skeletal myotube models and is triggered by cellularization but not directly related to MT disruption. In support of this, MT destabilization principally retards the fusion of myoblasts during skeletal myogenesis [Gundersen et al., 1989] . Similarly, mammalian cardiac myocytes retain the ability to breakdown myofibrils during division at the embryonic stage of development [Ahuja et al., 2004] . This ability to divide is soon lost in neonates following cardiac myocyte differentiation and the arrest of hyperplasia [Leu et al., 2001] . Currently, the molecular events behind this inability to breakdown sarcomeres following muscle differentiation are unknown. While the precise mechanism by which myoseverin breaks down sarcomeres is yet to be determined, its capacity for dual inhibition of sarcomeres and MTs represents a unique tool for future studies into the interplay of these cytoskeletal arrays in cardiac and skeletal muscle.
